Impact of Checkpoint Inhibitor Immunotherapy, Primarily Pembrolizumab, on Infection Risk in Patients With Advanced Lung Cancer: A Comparative Retrospective Cohort Study

Alexandre Malek(Louisiana State University Health Sciences Center Shreveport), Issam Raad(Missouri Department of Agriculture), Patrick Chaftari(The University of Texas MD Anderson Cancer Center), Melissa Khalil(The University of Texas MD Anderson Cancer Center), Ray Hachem(The University of Texas MD Anderson Cancer Center), George M. Viola(The University of Texas MD Anderson Cancer Center), Dimitrios P. Kontoyiannis(The University of Texas MD Anderson Cancer Center), Victor E. Mulanovich(The University of Texas MD Anderson Cancer Center), Anne Marie Chaftari(The University of Texas MD Anderson Cancer Center), Ying Jiang(The University of Texas MD Anderson Cancer Center), Johny Fares(The University of Texas MD Anderson Cancer Center), Frank V. Fossella(Ontario Institute for Cancer Research)
Clinical Infectious Diseases
June 12, 2020
Cited by 15


Related Papers